Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Inclusion Criteria

• •Voluntarily gives informed consent
• •Must meet criteria for lung transplant referral but is not required to be on an active lung transplant list
• •Stable and significant diffuse parenchymal lung disease with a diagnosis of interstitial lung disease
• •6MWD greater than or equal to 75 meters
• •Right heart catheterization with a mean pulmonary arterial pressure \>= 30 mgHg, pulmonary capillary wedge pressure \<= 15 mmHg and pulmonary vascular resistance \> 240 dynes
• •Echo-Doppler examination showing evidence of right ventricular dysfunction and normal left diastolic ventricular function
• •Either not receiving any PAH-approved oral therapy, or is receiving monotherapy (ERA, PDE-5I, or riociguat) for \> 60 days and receiving a stable dose for \> 30 days prior to enrollment
• •Able to communicate effectively with study personnel and will to be cooperative with protocol requirements